IXS - Innexus Biotechnology Inc (TSXV) - Page 35

No follow-through on $0.11 and we're back to retest the bottom. As the chart says, time to see what IXS is made of.

Right now it's made of .10 and looks like it could go to .085 or .09

Do you think they will let us know if they have funding first or do you think they are waiting for FDA approval first before they look for the funding?
Any thoughts on a timeline on when some more news is expected? I was a little dissapointed at what came out last week and thought we may have been told a hint of new news but it pretty well seems the same.

Concurrently, InNexus announces the resignations of Glenn Williamson and Laurence Luke from the company's Board of Directors, effective March 6, 2009. Chairman Jeff Morhet commented, "I thank Mr. Williamson and Mr. Luke for the work and support of InNexus over the last two years. The entire Board also thanks them for their contribution." Their decision to leave the Company's Board is not based on or reflective of any disagreement related to the Company's operations, policies or practices. The Company does not intend on replacing the Directors at this point and this supports other cost-saving measures

I don't know how much longer things can go without some sort of change

picked some up at .08 this morning, surprised it has gone this low.

I'm looking for a consensus of who's keeping the faith on this one. Are you still in this for the long haul?

Ty for your responses.

yup

I like the results but management has put out 3 nearly identical PRs in recent months. Clearly, they haven't attracted big fish (yet, perhaps). The story is an interesting one so I'm holding a few at ~0.11-0.09 and if/when big buyers arrive, I'll likely add a few more. Unfortunately, IXS hasn't been able to take advantage of the recent MOMO across the indices. IMO.

Got in when I was at 13 cents. Lost too much now to leave. I believe this could pay off big time but I am not impredded with the way things have been going on with management. At least we deserve to know what the plan is and where we are at.

long

Until I see negative news I am here. Have never sold a share in 2 years.

just averaged down a little @.075

Something has got the market's interest today on IXS..

On a down market day too... we just touched 11 cents.

I got some at 8 yesterday and 8.5 this morning.

Volume today is nice too.

ixs

maybe just maybe news tomorrow.

Freaking scumbags. Always out for theirselves.

seems resistance at .09.....so I picked up more on an otherwise down day for markets.

LEON, Spain & BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX Venture: IXS) (OTCBB: IXSBF) and Genhelix Biopharmaceutical Company announced today the signing of a Letter of Intent to set the stage for a planned strategic collaboration to focus on developing novel antibodies engineered with InNexus’ DXL™ technology.

The research and licensing agreement between the collaborators is expected to be completed later this year. InNexus will conduct preclinical development for a DXL™ therapeutic against an undisclosed target, with Genhelix providing GMP production and commercial manufacturing. DXL™ antibodies are biologics engineered with the novel ability to link with one another (self-binding) upon reaching their target, exhibiting marked enhancements for ADCC and CDC functions over the source antibody.

News of the planned alliance follows InNexus’ recently announced successful meeting with the FDA, where the agency expressed clear support for the company’s product development plans following a comprehensive review of the proposed clinical pathway for its lead preclinical candidate, DXL625 (CD20) for the prospective treatment of non-Hodgkin’s lymphoma and/or chronic lymphocytic leukemia. The agency also provided a Manufacturing Exception Approval allowing InNexus to manufacture all clinical material needed for DXL625’s Phase l human trial, in its facilities located on the campus of Mayo Clinic in Scottsdale, Arizona.

Speaking on the announcement, David Marcos Martinez, Chief Executive Officer of Genhelix, said, “The antibody industry is growing at an unprecedented rate. Today, it is estimated to have over $30 billion in worldwide sales, and antibodies are expected to be the pharmaceutical industry’s leading choice for the development of new therapeutic compounds. We are excited to be working with Mr. Morhet, his team and the partnership, as both organizations have enormous potential.”

Jeff Morhet, Chief Executive Officer of InNexus, said, “Our organizations are poised to strategically collaborate as partners focused on the development of new products, while maintaining our respective business competencies. This collaboration provides significant opportunities for both companies, and represents a creative approach to partnering that brings resources and capabilities together while the partners stay focused.”

About Genhelix Biopharmaceutical Company

Genhelix is an independent biotechnology-based company devoted to the manufacturing of biopharmaceutical products through the application of mammalian cell culture technology under contract manufacturing agreements. The mission of the company is to produce high-value active compounds in the fields of anti-cancer, cardiovascular or immunology therapies. Applied technologies are based on monoclonal antibody manufacturing. Genhelix currently has agreements with leading biotechnological companies from Europe, America and Japan. To learn more about Genhelix, please visit www.genhelix.com.

About InNexus Biotechnology Inc.

InNexus is a public biotechnology company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. InNexus Biotechnology Inc. is listed on the TSX Venture Exchange (TSX Venture: IXS) and the NASD OTCBB (OTCBB: IXSBF). To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.

news

All positive

Sure...

Though, I'm itching to read their next financial statement...

It sure didn't do much to interest people into buying much. Shareprice has actually been dropping.
I still am holding my small amount I have.